Prognostic value of diffuse reduction of spleen density on postoperative survival of pancreatic ductal adenocarcinoma: A retrospective study
- 7 February 2023
- journal article
- research article
- Published by Wiley in Asia-Pacific Journal of Clinical Oncology
- Vol. 20 (2) , 275-284
Abstract
It is difficult to predict the prognosis of patients with pancreatic ductal adenocarcinoma (PDAC) before radical operation. The purpose of this study was to explore the connection between the diffuse reduction of spleen density on computed tomography (DROSD) and the postoperative prognosis of patients with PDAC. A total of 160 patients with PDAC who underwent radical surgery in the First Affiliated Hospital of Wenzhou Medical University were enrolled. Cox regression analysis was used to cast the overall survival (OS) and evaluate the prognostic factors. Nomogram was used to forecast the possibility of 1-year, 3-year, and 5-year OS. The prediction accuracy and clinical net benefit are performed by concordance index (C-index), calibration curve, time-dependent receiver operating characteristics (tdROC), and decision curve analysis. In multivariable Cox analysis, DROSD is independently related to OS. Advanced age, TNM stage, neutrophil/lymphocyte ratio, and severe complications were also independent prognostic factors. The calibration curves of nomogram showed optimal agreement between prediction and observation. The C-index of nomogram is 0.662 (95%CI, 0.606-0.754). The area under tdROC curve for a 3-year OS of nomogram is 0.770. DROSD is an independent risk factor for an OS of PDAC. We developed a nomogram that combined imaging features, clinicopathological factors, and systemic inflammatory response to provide a personalized risk assessment for patients with PDAC.Keywords
Funding Information
- National Natural Science Foundation of China (82072685)
This publication has 38 references indexed in Scilit:
- Pancreatic Ductal Adenocarcinoma Radiology Reporting Template: Consensus Statement of the Society of Abdominal Radiology and the American Pancreatic AssociationGastroenterology, 2014
- Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro StudyPLOS ONE, 2013
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and PromotionScience, 2011
- Nutritional predictors of postoperative outcome in pancreatic cancerBritish Journal of Surgery, 2010
- Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2010
- The Immune System — is it Relevant to Cancer Development, Progression and Treatment?Clinical Oncology, 2008
- Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to InvasionCancer Research, 2007
- Structure and function of the spleenNature Reviews Immunology, 2005
- X-TileClinical Cancer Research, 2004
- Mass estimates by computed tomography: physical density from CT numbersAmerican Journal of Roentgenology, 1984